Global Gene Panel Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Gene Panel Market Analysis

The gene panel market has been experiencing significant growth driven by advancements in genomics and personalized medicine. Gene panels, which involve analyzing multiple genes simultaneously for diagnostic, predictive, and research purposes, have become essential tools in identifying genetic predispositions and managing various diseases, including cancer, cardiovascular disorders, and rare genetic conditions. Recent advancements in next-generation sequencing (NGS) technology have made gene panel testing more accurate, faster, and cost-effective. The development of customized gene panels allows for targeted genetic testing that can be tailored to individual patient needs, enhancing the efficiency of disease diagnosis and treatment plans. In addition, bioinformatics tools and artificial intelligence are playing key roles in analyzing complex genetic data, enabling better interpretation and understanding of results. The market is further driven by growing awareness of personalized healthcare and the need for precision medicine, with applications in cancer risk assessment, diagnosis, and pharmacogenetics. With increasing government support for genomics research and expanding healthcare infrastructure globally, the gene panel market is poised for continuous growth, making significant contributions to medical diagnostics and treatment innovation.

Gene Panel Market Size

The global gene panel market size was valued at USD 2.66 billion in 2024 and is projected to reach USD 4.97 billion by 2032, with a CAGR of 8.10% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gene Panel Market Trends

“Rise of Customized Gene Panels Tailored to Individual Patient Profiles”

A significant trend in the gene panel market is the rise of customized gene panels tailored to individual patient profiles, enhancing the accuracy and relevance of genetic testing. Unlike predesigned panels that focus on specific sets of genes, customized panels offer flexibility, allowing healthcare providers to target genes most relevant to a patient’s condition or risk factors. For instance, in oncology, personalized gene panels can identify unique genetic mutations in tumors, aiding in targeted treatment plans and precision medicine. This shift towards personalized diagnostics is supported by advancements in next-generation sequencing (NGS), which provides comprehensive genetic analysis with higher speed and lower costs. The integration of bioinformatics tools further aids in the interpretation of complex genetic data, enabling clinicians to make more informed decisions. This trend is expected to drive the market, meeting the growing demand for tailored healthcare solutions that improve patient outcomes and treatment efficacy.

Report Scope and Gene Panel Market Segmentation 

Gene Panel Market Definition

A gene panel is a diagnostic tool that tests multiple genes simultaneously to identify genetic variations associated with specific diseases or conditions. It is used to assess a person's genetic predisposition, aid in disease diagnosis, and guide treatment decisions, particularly in the fields of oncology, cardiology, and rare genetic disorders. Gene panels can be predesigned, focusing on a specific set of genes linked to a particular condition, or customized to target genes relevant to a patient's individual health profile.

Gene Panel Market Dynamics

Drivers

• Rising Demand for Personalized Medicine

The rising demand for personalized medicine is a significant driver of the gene panel market, as healthcare continues to shift towards more tailored approaches that prioritize individual patient needs. Gene panels play a crucial role in identifying specific genetic markers that help inform personalized treatment plans and optimize drug prescriptions, leading to better outcomes and reduced side effects. For instance, in oncology, gene panels are used to analyze tumor DNA to identify specific mutations, enabling targeted therapies that are more effective than traditional treatments. The use of NGS technology in these panels allows for comprehensive genetic profiling, facilitating the selection of precision treatments such as targeted inhibitors or immunotherapies. The increasing application of gene panels for personalized treatment in rare genetic diseases, such as cystic fibrosis and Huntington's disease, further highlights the shift toward personalized healthcare. This growing trend toward tailored medicine is fueling the demand for gene panels and driving expansion in the market.

• Increasing Awareness of Genetic Testing

Increasing awareness of genetic testing has become a major driver of the gene panel market, as both the public and healthcare professionals recognize the benefits of early diagnosis, risk assessment, and disease prevention. Educational initiatives and campaigns by organizations such as the American Cancer Society and various public health agencies have highlighted how genetic testing can detect predispositions to conditions such as breast cancer and hereditary heart diseases, leading to early interventions and preventive care. For instance, the use of gene panels to identify BRCA1 and BRCA2 gene mutations helps guide preventive measures such as prophylactic surgeries or targeted therapies for individuals at high risk of developing breast cancer. This growing recognition has contributed to increased adoption of gene panels as a vital tool in clinical practice, supporting their integration into routine healthcare and fueling market growth. The rising demand for comprehensive genetic information to make informed healthcare decisions further propels the expansion of the gene panel market.

 Opportunities

• Increasing Government Support and Funding

Government support and funding have emerged as significant factors accelerating the growth of the gene panel market, creating ample market opportunities. Governments and healthcare organizations around the world are recognizing the importance of genomics research and personalized medicine in improving patient outcomes and reducing long-term healthcare costs. For instance, the U.S. National Institutes of Health (NIH) has invested substantial resources into the All of Us Research Program, which aims to gather genomic and health data from diverse populations to support the development of personalized treatments. Similarly, initiatives such as the UK’s Genomics England project have highlighted the use of gene panels in identifying genetic disorders and tailoring treatments to individual patients, advancing precision medicine. These government-backed programs provide funding for research, encourage collaborations, and facilitate the adoption of gene panel testing in clinical settings. This financial support and strategic emphasis on personalized healthcare present significant growth opportunities for companies involved in the development and distribution of gene panels.

• Increasing Technological Innovations

Technological innovations have significantly enhanced the capabilities of gene panels, transforming complex genetic information into more manageable and actionable insights for clinical use. The integration of bioinformatics tools and artificial intelligence (AI) has streamlined data analysis, improving the accuracy and speed of interpreting gene panel results. For instance, AI-driven algorithms can analyze vast amounts of genomic data quickly to identify patterns and predict disease risk, aiding clinicians in making more informed decisions. Companies such as Illumina Inc. and Thermo Fisher Scientific are leveraging these advanced technologies to offer comprehensive genomic profiling solutions that are faster and more cost-effective. The application of AI in gene panel analysis helps detect subtle genetic variations that might be missed with traditional methods, improving the precision of diagnostics and treatment plans. This integration of technology represents a significant market opportunity, as healthcare providers and research institutions increasingly seek advanced tools to enhance personalized medicine and patient care.

Restraints/Challenges

• High Cost of Genetic Testing and Analysis

The high cost of genetic testing and analysis, particularly for comprehensive gene panels, is a significant market challenge as it limits patient access and adoption rates. For instance, comprehensive gene panels that screen for multiple genetic conditions or susceptibilities can cost thousands of dollars, making them unaffordable for many individuals, especially those without robust insurance coverage. In regions where insurance plans do not fully cover genetic testing or where high co-pays are required, patients may be unable or unwilling to pursue such diagnostics, resulting in missed opportunities for early disease detection or personalized treatment strategies. This economic barrier can perpetuate disparities in healthcare, preventing certain populations from benefiting from advancements in genetic medicine. The financial challenges associated with gene panel testing can stifle market growth, discourage innovation, and slow the integration of genetic testing into standard medical care.

• Privacy and Ethical Concerns

Privacy and ethical concerns are a major challenge for the gene panel market, as the use of genetic information raises significant issues related to data protection and potential misuse. For instance, individuals may fear that their genetic data could be accessed by third parties, such as employers or insurance companies, leading to genetic discrimination where individuals are denied employment or coverage based on their genetic predisposition to certain conditions. This fear can deter people from opting for genetic testing, limiting the market's growth and affecting the widespread adoption of gene panels. Moreover, stringent data protection regulations, such as the General Data Protection Regulation (GDPR) in the European Union, require companies to implement costly security measures and compliance procedures, further increasing operational expenses. These privacy and ethical concerns can create hesitancy among consumers and healthcare providers and challenge the integration of genetic testing into routine medical practice, posing a significant obstacle for market expansion.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gene Panel Market Scope

The market is segmented on the basis of product and service, technique, design, application, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Service

• Test Kits
• Testing Services

Technique

• Amplicon-Based Approach
• Hybridization-Based Approach

Design

• Predesigned Gene Panels
• Customized Gene Panels

Application

• Cancer Risk Assessment
• Diagnosis
• Pharmacogenetics

End-User

• Hospitals and Clinics
• Research Organizations and Academic Institutes

Gene Panel Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product and service, technique, design, application, and end-user channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the gene panel market, driven by a surge in research focused on cancer and rare inherited diseases. The region has seen significant growth in the use of NGS-based technologies and clinical applications, bolstered by strong government support for genomics research initiatives. In addition, the presence of prominent next-generation sequencing (NGS) providers in North America further fuels the market's expansion. These factors collectively make North America a dominant force in the gene panel sector.

Asia-Pacific is anticipated to be the fastest-growing region in the gene panel market, driven by heightened awareness of healthcare and a growing emphasis on preventive medicine. The region is witnessing an increasing demand for advanced medical technologies, including genetic testing and personalized healthcare solutions. Improved access to healthcare infrastructure and advancements in genomics research contribute to this growth trend. These factors position Asia-Pacific as a key player in the expanding gene panel market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Gene Panel Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Gene Panel Market Leaders Operating in the Market Are:

• BGI (China)
• Illumina, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Eurofins Scientific (Luxembourg)
• QIAGEN (Netherlands)
• OriGene Technologies, Inc. (U.S.)
• BIONEER CORPORATION (South Korea)
• GenScript (China)
• Kaneka Eurogentec S.A. (Belgium)
• Twist Bioscience (U.S.)
• BioCat GmbH (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Novogene Co., Ltd (China)
• Azenta Life Sciences (U.S.)
• Integrated DNA Technologies, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Labcorp Genetics Inc. (U.S.)

Latest Developments in Gene Panel Market

• In June 2023, Centogene N.V. expanded its collaboration with Agios Pharmaceuticals to develop improved therapies for genetically validated diseases using PYRUKYND (mitapivat). This first-in-class selective small molecule activator of the pyruvate kinase enzyme was approved by the U.S. FDA in February 2021
• In May 2023, Unipath Specialty Laboratory in India launched the HRD Gene Panel utilizing SOPHiA GENETICS technology. This initiative is expected to contribute significantly to advancements in the cancer genomics field
• In April 2023, Agilent Technologies, Inc. introduced an NGS assay designed for somatic variant profiling across various solid tumors, which aims to enhance precision oncology through comprehensive genomic profiling (CGP)
• In May 2022, Illumina Inc. added a companion diagnostic kit to its CE-marked product list. This was Europe’s first-in-class IVD TruSight Oncology (TSO) comprehensive assay to receive the CE mark distinction
• In March 2022, Eurofins Genomics supported ‘Our Future Health’, the UK’s largest health analysis program, to genotype five million people and build an extensive representation of the UK’s population health. This initiative aims to aid in the prevention, diagnosis, and treatment of diseases

SKU-59756